Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to results published in Allergy.&ldquo ...

Key takeaways: Dupilumab is the first drug approved for treating children with eosinophilic esophagitis. The safety profile in children was similar to the safety profiles for adolescents and adults.

Health Canada has issued a Notice of Compliance (NOC) for DUPIXENT® (dupilumab injection) for the treatment of patients aged 1 year and older, weighing at least 15 kg, with eosinophilic ...

Dupilumab is a monoclonal antibody that acts to inhibit part of the inflammatory pathway. EoE KIDS Trial The FDA approval of dupilumab for younger children is based on results from the phase 3 ...

Patients with AD treated with dupilumab have a lower risk of various infections than those treated with methotrexate or cyclosporine.

The trial found that a higher-exposure dupilumab regimen improved key secondary endpoints in children.

“The NEJM publication of these Phase 3 dupilumab results is a testament to the importance of these data and potential for dupilumab to change the standard of care for many young children with ...

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis ...

Children were randomized to receive a subcutaneous injection of dupilumab or placebo in addition to their standard therapy every two weeks for a year. Neither investigators nor participants knew who ...

DUPIXENT® has since been approved for the treatment of adolescents, children and infants aged 6 months and older with moderate-to-severe atopic dermatitis; adults with chronic rhinosinusitis with ...

Results from the trial were published in The New England Journal of Medicine. About Dupixent Dupixent is an injection administered under the skin (subcutaneous injection) at different injection sites.

Health Canada has issued a Notice of Compliance (NOC) for DUPIXENT® (dupilumab injection) for the treatment of patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis ...